公开(公告)号：US20170306049A1

公开(公告)日：2017-10-26

申请号：US15508112

申请日：2015-09-08

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Yosef YARDEN ,  Nadège GABORIT ,  Moshit LINDZEN

IPC: C07K16/32 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a KD value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HERS and NRG-induced cancer cell migration and proliferation.

公开(公告)号：US20170002068A1

公开(公告)日：2017-01-05

申请号：US15271515

申请日：2016-09-21

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Silvia CARVALHO ,  Moshit LINDZEN

IPC: C07K16/22 ,  G01N33/574 ,  A61K31/704 ,  A61K45/06 ,  A61K33/24

CPC classification number: C07K16/22 ,  A61K31/704 ,  A61K33/24 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  G01N33/57407 ,  G01N33/57438 ,  G01N33/57449 ,  G01N2333/485 ,  G01N2333/495 ,  G01N2800/52

Abstract: A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.

Abstract translation: 本发明提供一种测定受试者用抗双抗调素抗体治疗的适应性的方法，其中所述受试者具有选自卵巢癌，头颈部癌症和表现出抗化学疗法的胰腺癌的癌症。 所述方法包括在生物样品中分析双调蛋白，转化生长因子α（TGF-α）和肝素结合表皮生长因子（HB-EGF）的受试者表达水平，其中所述双调蛋白的表达水平高于预定阈值 并且TGF-α和/或HB-EGF的表达或低于TGF-α和/或HB-EGF的预定水平的表达不表示受试者用抗两性调节蛋白抗体治疗的适合性 。 还提供了治疗癌症的方法，以及抗体和药物组合物。

公开(公告)号：US20240156959A1

公开(公告)日：2024-05-16

申请号：US18544514

申请日：2023-12-19

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Ashish NORONHA

IPC: A61K39/395 ,  A61K31/502 ,  A61K31/506 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/502 ,  A61K31/506 ,  A61P35/00

Abstract: A method of treating cancer in a subject in need thereof is disclosed wherein cancer cells of the subject express an EGFR having a mutation in a kinase domain of the receptor. The method comprises administering to the subject a therapeutically effective amount of: (i) an anti-epidermal growth factor receptor (anti-EGFR) antibody; (ii) an AXL inhibitor, and optionally (iii) a tyrosine kinase inhibitor (TKI). Also disclosed is a new anti-AXL antibody.

公开(公告)号：US20180327488A1

公开(公告)日：2018-11-15

申请号：US16044636

申请日：2018-07-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Silvia CARVALHO ,  Moshit LINDZEN

IPC: C07K16/22 ,  A61K45/06 ,  A61K31/704 ,  A61K33/24

CPC classification number: C07K16/22 ,  A61K31/704 ,  A61K33/24 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  G01N33/57407 ,  G01N33/57449 ,  G01N2033/57461 ,  G01N2333/485 ,  G01N2333/495 ,  G01N2800/52

Abstract: A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.

公开(公告)号：US20170196888A1

公开(公告)日：2017-07-13

申请号：US15321281

申请日：2015-06-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Mattia LAURIOLA

IPC: A61K31/573 ,  A61K9/00 ,  A61K31/517

CPC classification number: A61K31/573 ,  A61K9/0053 ,  A61K31/517 ,  A61K45/06 ,  A61K2300/00

Abstract: A method of treating cancer in a subject in need thereof is provided. The method comprising administering to the subject a receptor tyrosine kinase (RTK)-specific cancer therapy and a glucocorticoid or a glucocorticoid analog, such that an efficacy window of said RTK-specific cancer therapy and an efficacy window of said glucocorticoid or glucocorticoid analog substantially overlap.

公开(公告)号：US20170165285A1

公开(公告)日：2017-06-15

申请号：US15438806

申请日：2017-02-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Nir BEN-CHETRIT

IPC: A61K31/7048 ,  C07K16/30 ,  A61K31/366 ,  A61K31/7034 ,  A61K31/353 ,  A61K31/05 ,  A61K31/12 ,  A61K31/7032 ,  A61K31/155 ,  A61K31/4709 ,  A61K31/216 ,  A61K31/235 ,  A61K38/17 ,  A61K31/704

CPC classification number: A61K31/7048 ,  A61K31/05 ,  A61K31/12 ,  A61K31/155 ,  A61K31/216 ,  A61K31/235 ,  A61K31/353 ,  A61K31/366 ,  A61K31/4709 ,  A61K31/7032 ,  A61K31/7034 ,  A61K31/704 ,  A61K38/179 ,  A61K39/0011 ,  A61K45/06 ,  C07K16/30 ,  G01N33/57415 ,  A61K2300/00

Abstract: A method of preventing tumor metastasis with the proviso that the tumor is not glioma is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an inhibitor of synaptojanin 2 (SYNJ2), thereby preventing tumor metastasis. Also, provided is a method of treating cancer. The method comprising, administering to a subject in need thereof a therapeutically effective amount of an inhibitor of synaptojanin 2 (SYNJ2) and an inhibitor of a cell surface receptor associated with an onset or progression of cancer, thereby treating cancer.

公开(公告)号：US20180208674A1

公开(公告)日：2018-07-26

申请号：US15935010

申请日：2018-03-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Michael SELA ,  Ruth MARON ,  FERRARO Daniela Aleida

IPC: C07K16/32 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/32 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/507 ,  C07K16/2863 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77

Abstract: A method of treating triple negative breast cancer in a subject comprising administering to the subject a therapeutically effective amount of a combination of at least two anti epidermal growth factor receptor (EGF-R) antibodies exhibiting binding to different epitopes on the EGF-R, thereby treating triple negative breast cancer.

公开(公告)号：US20160152712A1

公开(公告)日：2016-06-02

申请号：US14956585

申请日：2015-12-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Maicol Mancini ,  Nadège Gaborit

IPC: C07K16/28 ,  A61K31/517 ,  A61N5/10 ,  C07K16/40 ,  A61K39/395 ,  C07K16/30 ,  A61K31/506

CPC classification number: C07K16/2863 ,  A61K31/506 ,  A61K31/517 ,  A61K39/39558 ,  A61K2039/507 ,  A61N5/10 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.

Abstract translation: 提供了治疗具有对酪氨酸激酶抑制剂（TKI）具有抗性的癌症患者的方法。 因此，提供了一种方法，其包括向受试者施用治疗有效量的抗体，其包含抗EGFR抗体，抗HER2抗体和抗HER3抗体。 还提供了用于治疗对TKI的耐癌性的组合物和制品。 还提供了治疗非耐药性肿瘤的方法。

公开(公告)号：US20210275545A1

公开(公告)日：2021-09-09

申请号：US17325355

申请日：2021-05-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Swati SRIVASTAVA

IPC: A61K31/567 ,  A61K31/496 ,  A61K31/4188 ,  A61K31/03 ,  A61K31/451 ,  A61K31/4174 ,  A61K31/444 ,  A61K31/437 ,  A61P35/00 ,  C12Q1/6886

Abstract: A method of treating a cancer selected from the group consisting of a myeloid malignancy, a lymphoid malignancy and Ewing's sarcoma is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol.

公开(公告)号：US20170042857A1

公开(公告)日：2017-02-16

申请号：US15100322

申请日：2014-11-27

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Yosef YARDEN ,  Nir BEN-CHETRIT

IPC: A61K31/353 ,  A61K31/7048 ,  A61K31/7024 ,  A61K31/12 ,  A61K45/06 ,  A61K31/155 ,  A61K31/4709 ,  A61K31/216 ,  A61K31/235 ,  A61K31/05 ,  A61K31/7028 ,  A61K31/7032

CPC classification number: A61K31/353 ,  A61K31/05 ,  A61K31/12 ,  A61K31/155 ,  A61K31/216 ,  A61K31/235 ,  A61K31/4709 ,  A61K31/7024 ,  A61K31/7028 ,  A61K31/7032 ,  A61K31/704 ,  A61K31/7048 ,  A61K45/06

Abstract: Disclosed herein are synaptojanin-2 inhibitors, and novel methods and uses utilizing same for preventing tumor metastasis, treating cancer or inhibiting synaptojanin-2. Compounds disclosed herein include chlorhexidine and pyrvinium, the compound having the formula: and compounds characterized by the general formula: X-L-[(Y)i-(Z)j]-(L-X)k and/or by the general formula: wherein L, X, Y, Z, D, E, i, j and k are as defined herein.

Abstract translation: 其中L，X，Y，Z，D，E，i，j和k如本文所定义。